{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:01:01Z","timestamp":1790762461141,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003921","name":"Australian Government Department of Health Disability and Ageing","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Western Pacific"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.lanwpc.2026.101982","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:58:43Z","timestamp":1790024323000},"page":"101982","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The epidemiological impact and effectiveness of herpes zoster vaccination among older and pharmacologically immunocompromised adults: a population-based observational study"],"prefix":"10.1016","volume":"74","author":[{"given":"Joanne","family":"Reekie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Stepien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Li-Kim-Moy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabeth","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4675-0232","authenticated-orcid":false,"given":"Kristine","family":"Macartney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0787-5825","authenticated-orcid":false,"given":"Bette","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanwpc.2026.101982_bib2","doi-asserted-by":"crossref","first-page":"6810","DOI":"10.1016\/j.vaccine.2018.08.080","article-title":"Cost of herpes zoster and herpes zoster-related complications among immunocompromised individuals","volume":"36","author":"Meyers","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.lanwpc.2026.101982_bib3","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1017\/S0950268814003653","article-title":"Risk factors for herpes zoster in a large cohort of unvaccinated older adults: a prospective cohort study","volume":"143","author":"Liu","year":"2015","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.lanwpc.2026.101982_bib4","first-page":"47","article-title":"ATAGI targeted review 2022: vaccination for prevention of herpes zoster in Australia","volume":"47","author":"Huang","year":"2023","journal-title":"Commun Dis Intell"},{"key":"10.1016\/j.lanwpc.2026.101982_bib5","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jinf.2022.01.011","article-title":"Impact of a national immunisation program on herpes zoster incidence in Australia","volume":"84","author":"Lin","year":"2022","journal-title":"J Infect"},{"key":"10.1016\/j.lanwpc.2026.101982_bib6","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the Herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanwpc.2026.101982_bib7","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted Herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanwpc.2026.101982_bib9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40121-022-00749-y","article-title":"Reduction in Herpes zoster antiviral use since the introduction of the live-attenuated zoster vaccine on Australia's national immunisation program: a population-based study from 1994 to 2019","volume":"12","author":"Phakey","year":"2023","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.lanwpc.2026.101982_bib10","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1080\/21645515.2020.1754702","article-title":"Early impact of the Australian national shingles vaccination program with the herpes zoster live attenuated vaccine","volume":"16","author":"Litt","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.lanwpc.2026.101982_bib12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/aje\/kwx245","article-title":"Long-term effectiveness of the live zoster vaccine in preventing shingles: a cohort study","volume":"187","author":"Baxter","year":"2018","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.lanwpc.2026.101982_bib13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2147\/CIA.S494145","article-title":"Validity of the updated Rx-Risk index as a disease identification and risk-adjustment tool for use in observational health studies","volume":"20","author":"Widagdo","year":"2025","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.lanwpc.2026.101982_bib14","doi-asserted-by":"crossref","first-page":"136","DOI":"10.17713\/ajs.v54i4.2131","article-title":"cellKey-An R package to perturb statistical tables","volume":"54","author":"Meindl","year":"2025","journal-title":"Austrian Journal of Statistics"},{"issue":"7","key":"10.1016\/j.lanwpc.2026.101982_bib15","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1017\/S0950268814002222","article-title":"Control of varicella in the post-vaccination era in Australia: a model-based assessment of catch-up and infant vaccination strategies for the future","volume":"143","author":"Gao","year":"2015","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.lanwpc.2026.101982_bib16","doi-asserted-by":"crossref","first-page":"s16","DOI":"10.1136\/bmj.s16","article-title":"Is the chickenpox vaccine safe, and why is it now being offered to UK children?","volume":"392","author":"Lang","year":"2026","journal-title":"BMJ"},{"key":"10.1016\/j.lanwpc.2026.101982_bib17","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/cid\/ciab125","article-title":"Recombinant zoster vaccine (Shingrix): real-world effectiveness in the first 2 years post-licensure","volume":"73","author":"Izurieta","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanwpc.2026.101982_bib18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.7326\/M23-2023","article-title":"Effectiveness of recombinant zoster vaccine against herpes zoster in a real-world setting","volume":"177","author":"Zerbo","year":"2024","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lanwpc.2026.101982_bib19","doi-asserted-by":"crossref","first-page":"e717","DOI":"10.1093\/cid\/ciaf329","article-title":"Effectiveness of the adjuvanted recombinant zoster vaccine in adults \u226550 years in the United States","volume":"81","author":"Tseng","year":"2026","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanwpc.2026.101982_bib20","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2263979","article-title":"Effectiveness and safety of recombinant zoster vaccine: a review of real-world evidence","volume":"19","author":"Parikh","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.lanwpc.2026.101982_bib21","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/infdis\/jiw047","article-title":"Declining effectiveness of herpes zoster vaccine in adults aged \u226560 years","volume":"213","author":"Tseng","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.lanwpc.2026.101982_bib22","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanwpc.2026.101982_bib23","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/cid\/ciz177","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase 3, randomized clinical trial","volume":"70","author":"Vink","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanwpc.2026.101982_bib24","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.vaccine.2022.10.063","article-title":"Safety and efficacy of recombinant and live herpes zoster vaccines for prevention in at-risk adults with chronic diseases and immunocompromising conditions","volume":"41","author":"Sullivan","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.lanwpc.2026.101982_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.128124","article-title":"Herpes zoster vaccination among immunocompromised adults in the United States","volume":"72","author":"Carrico","year":"2026","journal-title":"Vaccine"},{"key":"10.1016\/j.lanwpc.2026.101982_bib26","doi-asserted-by":"crossref","first-page":"247","DOI":"10.5694\/mja2.50971","article-title":"COVID-19 and changes in the National Immunisation Program: a unique opportunity to optimise the Australian Immunisation Register (AIR)","volume":"214","author":"Tuckerman","year":"2021","journal-title":"Med J Aust"},{"key":"10.1016\/j.lanwpc.2026.101982_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.978203","article-title":"Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: a systematic review and network meta-analysis","volume":"13","author":"Xia","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.lanwpc.2026.101982_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2023.100397","article-title":"Efficacy and safety of the recombinant zoster vaccine: a systematic review and meta-analysis","volume":"15","author":"Zeevaert","year":"2023","journal-title":"Vaccine X"},{"key":"10.1016\/j.lanwpc.2026.101982_bib30","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2278362","article-title":"Recombinant zoster vaccine in immunocompetent and immunocompromised adults: a review of clinical studies","volume":"19","author":"Mwakingwe-Omari","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.lanwpc.2026.101982_bib31","article-title":"Increasing trends of herpes zoster in Australia","volume":"10","author":"MacIntyre","year":"2015","journal-title":"PLoS One"}],"container-title":["The Lancet Regional Health - Western Pacific"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606526001860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606526001860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:16:05Z","timestamp":1790759765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666606526001860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":27,"alternative-id":["S2666606526001860"],"URL":"https:\/\/doi.org\/10.1016\/j.lanwpc.2026.101982","relation":{},"ISSN":["2666-6065"],"issn-type":[{"value":"2666-6065","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The epidemiological impact and effectiveness of herpes zoster vaccination among older and pharmacologically immunocompromised adults: a population-based observational study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Western Pacific","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanwpc.2026.101982","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101982"}}